Stay updated on Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.

Latest updates to the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page
- Check3 days agoChange DetectedThe page's revision/build identifier was updated from v3.6.0 to v3.6.2, indicating a minor update to the page build. This change does not alter the study details or eligibility information presented on the page.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedEditorial updates on the study record page add sponsor identifiers (Aiping Zhou and Chinese Academy of Medical Sciences) and new help/navigation items (How to Read a Study Record, Common Questions, How to Join a Study). The revision tag is updated to v3.6.0, and some older verification-related lines were removed.SummaryDifference2%

- Check24 days agoChange DetectedA new revision tag 'Revision: v3.5.5' is added, replacing the previous 'Revision: v3.5.4', reflecting an update to the page's revision history.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4. This reflects an updated version of the study record, without altering the reported study details.SummaryDifference0.1%

- Check67 days agoChange DetectedThe page footer revision was updated from v3.5.2 to v3.5.3, indicating a minor site/version update without changing the study information presented.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.